Portal de Periódicos da CAPES

Quality of life outcomes of combination zidovudine–didanosine–nevirapine and zidovudine–didanosine for antiretroviral-naive advanced HIV-infected patients

2000; Lippincott Williams & Wilkins; Volume: 14; Issue: 16 Linguagem: Inglês

10.1097/00002030-200011100-00020

1473-5571

Raffaella Bucciardini, Albert W. Wu, Marco Floridia, Vincenzo Fragola, D. Ricciardulli, Carlo Tomino, Liliana Elena Weimer, Maria Franca Pirillo, M. Mirra, Massimo Marzi, Giacomo Giannini, Clementina Maria Galluzzo, Mauro Andreotti, Maurizio Massella, Stefano Vella,

HIV Research and Treatment

Objectives To evaluate the quality of life outcomes in antiretroviral-naive patients randomized to zidovudine plus didanosine versus zidovudine plus didanosine plus nevirapine for treatment of advanced HIV disease (the Istituto Superiore di Sanità 047 trial). Design A 48-week randomized, double-blind trial. Methods Sixty patients were enrolled and evaluated over 24 weeks. Quality of life was assessed using a modified version of the Medical Outcomes Study-HIV Health Survey. For analysis, we calculated two summary scores reflecting the physical (PHS) and the mental (MHS) components of health. Results Although the three-drug combination was superior at inducing immunologic and virologic responses, the two-drug regimen was superior for both PHS and MHS, especially at week 8 where differences were both statistically and clinically significant (5.8 and 9.2 points, respectively, P < 0.02 for both). Quality of life changes paralleled trends in body weight and Karnofsky performance status score. Conclusion Although a three-drug antiretroviral therapy regimen was superior in terms of short term virologic/immunologic response, the two-drug regimen was better in terms of quality of life. In general, triple therapy remains the most effective treatment option. However, quality of life assessments can yield results that may be discordant with and complementary to those obtained using conventional endpoints. Comparative trials should collect a comprehensive range of outcome measures, including patient-reported quality of life, in order to provide clinicians and patients with additional information that may influence treatment decisions.